

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse DR3 in direct ELISAs and Western blots. In direct ELISAs, approximately 30% cross-reactivity with recombinant mouse (rm) DR6, rmTrail R2, and recombinant human (rh) Mer is observed, and approximately 20% cross-reactivity with rhDR3, rhT
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse DR3/TNFRSF25 Gln31-Phe199 Accession # AAK11256
Conjugate	Alexa Fluor 750 Excitation Wavelength: 749 nm Emission Wavelength: 775 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunohistochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Death receptor 3 (DR3), also known as TNFRSF25, LARD, WSL-1, APO3, TRAMP, and TR3, is a 55 kDa TNF receptor superfamily protein that is predominantly expressed by lymphocytes. TNF receptor superfamily members have varying numbers of extracellular cysteine-rich domains (CRDs) with conserved cysteine spacing (1, 2). DR3 contains four CRDs and one cytoplasmic death domain (3, 4). Alternative splicing of mouse DR3 generates an isoform that lacks the fourth CRD and a secreted isoform that consists of only the extracellular domain (ECD) (3). Human DR3 exists in at least eleven alternate splice forms (5). Within the ECD, mouse and human DR3 share 59% amino acid (aa) sequence identity. DR3 shares 20-28% aa sequence identity with the ECD of death domain receptors DR5, DR6, EDAR, Fas, NGF R, and TNF RI. Naïve B and T cells preferentially express truncated soluble isoforms of DR3, whereas stimulated lymphocytes preferentially express transmembrane DR3 (5). TL1A/TNFSF15, a high affinity DR3 ligand which also exists in membrane bound and soluble forms, is expressed by activated endothelial cells and T cells (6, 7). TL1A additionally binds to DcR3/TNFRSF6B, a soluble decoy receptor that interferes with DR3 activation (8). DR3 signaling triggers either apoptosis or NFκB-induced anti-apoptotic effects depending on the cellular setting (9). Apoptosis is partially impaired during negative selection of thymocytes in DR3-null mice (10). TL1A interactions with DR3 augment T cell proliferation and pro-inflammatory cytokine secretion (6, 7, 11, 12). DR3 is upregulated by inflammatory stimulation of CCR9⁺ T cells, a T cell subset important in mucosal immunity (11). T cell and macrophage DR3 expression is prominent in several inflammatory disorders such as Crohn's disease, inflammatory bowel disease, and atherosclerosis (7, 11-15). DR3 activation on IFN-γ treated THP-1 cells induces the production of TNF-α, CXCL8, CCL2, MMP-1, -9, and -13 (14, 15).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.